Core Insights - The article highlights the emergence of AI technologies in the pharmaceutical and medical fields, particularly focusing on the advancements made by Chinese AI company DeepSeek and its large model R1, which has gained recognition in the scientific community [2] - The integration of AI in drug discovery and clinical applications is accelerating, with significant investments from major pharmaceutical companies aiming to revolutionize the drug development process [4][5] Group 1: AI in Drug Discovery - Major pharmaceutical companies, including Bristol-Myers Squibb and Sanofi, are investing billions in AI drug discovery, hoping to achieve breakthroughs that will transform the drug development process [4] - Medidata's data indicates that the proportion of clinical trials initiated by Chinese companies has surged from approximately 3% to 30% by 2024, positioning China as the second-largest clinical trial market globally [4] - AI is expected to drive a new wave of drug development, becoming a crucial force in the transformation of new drug research [4] Group 2: AI in Medical Applications - The "Meta-Medical" laboratory, launched by Zhongshan Hospital affiliated with Fudan University, aims to develop AI agents and apply large model technologies to enhance medical knowledge digitization and productization of diagnostic capabilities [6] - AI is changing the paradigm of diagnosis and treatment, with significant advancements in areas such as heart disease risk prediction and real-time monitoring through wearable devices [6] - The successful application of AI in specific medical fields has reached clinical levels, exemplified by the monitoring of intermittent atrial fibrillation using wearable technology [6] Group 3: Challenges and Ethical Considerations - Despite the potential of AI in drug discovery, challenges remain, including a 90% failure rate in clinical trials and the need to address complex biological issues and regulatory hurdles [5] - Ethical considerations are paramount, with the responsibility for medical decisions still resting with physicians, who must ensure that AI technologies are used safely and effectively in clinical settings [7]

Group 1: AI in Drug Development - AI has become a significant focus for multinational pharmaceutical companies, with substantial investments aimed at transforming the drug discovery process and generating breakthroughs in understanding biological data [3][4] - The global proportion of clinical trials initiated by Chinese companies has increased from approximately 3% to 30% by 2024, positioning China as the second-largest clinical trial market [3] - AI is expected to drive a new wave of drug development, becoming a crucial force in the transformation of new drug research and development [3][4] Group 2: AI Applications in Medical Diagnosis - Major medical institutions in China are actively promoting the integration of large models and AI agents in clinical applications, exemplified by the launch of the "Meta-Medical Simulation Laboratory" by Fudan University and technology companies [5] - AI is changing the paradigm of diagnosis and treatment, with significant advancements in areas such as heart rate screening, imaging analysis, and risk assessment [6] - The application of AI in medicine involves three key aspects: data quality, computational power, and algorithm optimization, which are essential for effective clinical application [6] Group 3: Challenges and Considerations - Despite the potential of AI in drug discovery, there are significant challenges, including a 90% failure rate in clinical trials and the need to address complex biological and regulatory issues [4] - Ethical considerations are paramount, with the understanding that physicians remain the primary decision-makers in clinical settings, and the responsibility for medical actions lies with them [6]